


Powered by the Sharekhan 3R Research Philosophy



# What has changed in 3R MATRIX Old New RS ↔ RQ ↔ RV ↔

#### **Company details**

Market cap:	Rs. 1,15,975 cr
52-week high/low:	Rs. 143 / 76
NSE volume: (No of shares)	397.6 lakh
BSE code:	532461
NSE code:	PNB
Free float: (No of shares)	344.8 cr

#### Shareholding (%)

Promoters	70.1
FII	8.4
DII	11.7
Others	9.9

#### **Price chart**



#### Price performance

Sharekhan Research, Bloomberg

(%)	1m	3m	6m	12m
Absolute	-1.9	-12.2	-19.8	29.5
Relative to Sensex	2.5	-8.6	-24.8	11.3

## **Punjab National Bank**

RoA hits ~1%

Bank			Sharekhan code: PNB				
Reco/View: Buy		$\leftrightarrow$	CMP:	Rs. 101	l	Price Target: <b>Rs. 125</b>	$\downarrow$
	个	Upgrade	↔ Mai	ntain	$\downarrow$	Downgrade	

#### Summary

- PNB reported 145% y-o-y earnings growth aided by ~92% y-o-y decline in provisions and ~10% y-o-y growth in operating profit resulting in RoA/RoE at 1.0%/ 14.7%.
- Bad loan recoveries stayed strong leading to net slippages negative at Rs. 734 crore. Net NPL ratio touched ~0.46% (lowest in decadal) and better than its large peers.
- Business momentum was healthy. Advances/ deposits grew by 4% q-o-q/ 4% q-o-q. However, core PPoP was weak, declined by 11% y-o-y led by higher employee benefit provisions under IND AS-15 along with muted NII/ fee. NIMs fell by 15 bps q-o-q to 2.9%.
- Stock trades at 0.9x/ 0.8x its FY2025E/FY2026E ABV. We maintain Buy with a revised PT of Rs. 125, given bad loan recoveries to continue to drive profitability and support RoA trajectory as the overall bad loan pool is still quite large at ~Rs140,000 crore.

Strong asset quality trends continued to drive earnings and higher RoA for the bank although core operating performance was weak. NII at Rs. 10,517 crore (below estimates) grew by 6% y-o-y/flat q-o-q. NIMs declined by 15 bps q-o-q to ~2.92% by lower yields and a marginal increase in cost of funds. Core fee income grew by 15% y-o-y but declined by 24% q-o-q led by higher loan processing fee in the last quarter. Treasury gains were at Rs. 1,581 vs Rs. 648 crore q-o-q and Rs. 264 crore y-o-y. Other income (ex. treasury gains) stood at Rs. 1,410 crore versus Rs. 855 crore q-o-q and 1.389 crore y-o-y mainly comprising of recovery from written off account. Total operating expenses grew by 22% y-o-y/ 10% q-o-q mainly driven by higher employee benefit provisions under IND AS-15. Operating profit grew by 10% y-o-y/4% q-o-q. However, core PPoP (ex. treasury gains) declined by 11% y-o-y/ 11% q-o-q, was weak, led by higher employee benefit provisions and muted NII/ fee. Total provisions declined by 92% y-o-y/78% q-o-q. Core credit cost at 8 bps vs 32 bps q-o-q and 136 bps y-o-y. PAT at Rs. 4,303 crore (above estimates mainly led by lower credit cost) grew by 145% y-o-y/ 32% q-o-q. Net advances and deposits grew by 15% y-o-y/4% q-o-q and 11% y-o-y/4% q-o-q, respectively. Domestic CASA grew by 3% y-o-y/ 1% q-o-q. CASA ratio stood at 38.2% vs 39.0% of total deposits. Domestic term deposits grew by 17% y-o-y/ 4% q-o-q. Overseas deposits grew by 28% y-o-y/ 9% q-o-q. RAM advances grew by 12% y-o-y/ 3% q-o-q. Domestic corporate book grew by 11% y-o-y/ 2% q-o-q however, overseas book grew faster by 38% y-o-y/ 14% q-o-q but accounts for only ~4-5% of gross advances. Asset quality rose sharply with GNPA and NNPA ratios falling by 50 bps/14 bps q-o-q, respectively, to 4.48%/0.46%. PCR stood at ~90% versus 88% q-o-q. Net slippages were negative at Rs. 734 crore vs positive at Rs. 35 crore q-o-q. Total restructured book forms 0.8% of net advances vs 0.9% q-o-q. Total SMA1 & SMA2 book cumulatively stands at 2.8% of net advances.

#### Key positive

- Core credit continued to trend lower (at 8 bps annualised vs 32 bps q-o-q and 136 y-o-y) led by strong recoveries
- RoA improved by 20 bps q-o-q to 1.02%.
- Domestic term deposits grew by 17% y-o-y/ 4% q-o-q.

#### **Key negatives**

 Core PPoP declined by 11% y-o-y/ 11% q-o-q, was weak led by higher employee benefit provisions under IND AS-15 along with muted NII.

#### **Management Commentary**

- The bank is reasonably confident that bad loan recoveries would continue to drive profitability and support RoA trajectory of ~1% as the overall bad loan pool is still quite large at ~Rs. 140,000 crore.
- Credit cost for FY25E would be in the range 25-30 bps of avg advances.
- The bank maintained its conservative guidance on loan growth at ~11-12% in FY25 with a faster growth in RAM advances and has also maintained its guidance on NIMs at 2.9-3.0 until rate cuts starts.

#### Our Cal

**Valuation** – **Maintain Buy on PNB with a revised PT of Rs. 125:** Sustained improvement in asset quality is encouraging and outlook remains strong led by strong recoveries from bad loan pools. The net NPL ratio is below the large PSU banks. The bank is reasonably confident that bad loan recoveries would continue to drive profitability and support RoA trajectory of ~1% as the overall bad loan pool is still quite large at ~Rs. 140,000 crore. Also the bank has been guiding that quality of loans sanctioned in post-COVID times is far superior with very low delinquency. Business momentum is expected to remain healthy. At CMP, the stock trades at 0.9x/ 0.8x its FY2025E/FY2026E BV. We maintain Buy on PNB with a revised PT of Rs. 125 given risk reward is favourable given the recent underperformance and also it can now create buffers for the additional ECL provisioning requirement if any within the guided credit cost range and still report RoA at ~1%.

#### **Key Risks**

Economic slowdown, lower recoveries than anticipated, higher slippages, lower margins.

Valuation (Standalone)					Rs cr
Particulars	FY22	FY23	FY24	FY25E	FY26E
Net Interest Income	28,694	34,492	40,083	42,764	49,289
Net profit	3,458	2,507	8,245	16,103	18,220
EPS (Rs.)	3.2	2.3	7.5	14.0	15.9
P/E (x)	32.0	44.3	13.5	7.2	6.4
P/BV (x)	1.8	1.4	1.1	0.9	0.8
RoE	3.7	2.6	8.0	13.6	13.0
RoA	0.3	0.2	0.5	1.0	1.0

Source: Company; Sharekhan estimates

## Sharekhan by BNP PARIBAS

#### **Key result highlights**

- **NII growth muted:** Net interest income at Rs. 10,517 crore (below estimates) grew by 6% y-o-y/flat q-o-q. NIMs declined by 15 bps q-o-q to ~2.92% by lower yields and marginal increase in cost of funds. The bank is confident of maintaining NIMs at 2.9-3.0% until the rate cut starts.
- **Negligible credit cost reported:** Total provisions declined by 92% y-o-y/78% q-o-q. Core credit cost at 8 bps vs 32 bps q-o-q and 136 bps y-o-y. The bank expects credit cost to fall to 0.25-0.30% of advances versus earlier guidance of 0.5% in FY25E.
- Loan growth: Net advances grew by 15% y-o-y/4% q-o-q. Retail advances (excluding agri and MSME books) grew by 15% y-o-y/ 7% q-o-q. The agri loan and MSME book grew by 11% and 9% y-o-y, respectively. Overseas loan book grew by 38% y-o-y/ 14% q-o-q, accounts for only ~4-5% of gross advances. Domestic corporate book grew 11% y-o-y/2% q-o-q. The bank is eyeing ~11-12% loan growth in FY25E with a strong focus to grow the RAM segment faster. The guidance is bit conservative.
- **Deposit growth:** Total deposits grew by 11% y-o-y/4% q-o-q. Domestic CASA grew by 3% y-o-y/ 1% q-o-q. CASA ratio stood at 38.2% versus 39.0% of total deposits. Domestic term deposits grew by 17% y-o-y/ 4% q-o-q. Overseas deposits grew by 28% y-o-y/ 9% q-o-q. Avg. LCR stood at 129% versus 125% q-o-q. CD ratio was stable at 70% q-o-q.
- Asset quality continue to shine: The bank's asset quality improved sharply with GNPA and NNPA ratios falling by 50 bps/14 bps q-o-q, respectively, to 4.48%/0.46%. PCR stood at ~90% vs 88% q-o-q. Net slippages were negative at Rs. 734 crore vs positive at Rs. 35 crore q-o-q led by higher recoveries. Total restructured book forms 0.8% of net advances vs 0.9% q-o-q. Total SMA1 & SMA2 book cumulatively stands at 2.8% of net advances. The bank maintained its recovery target of Rs. 18,000 crore in FY25. The bank is reasonably confident that bad loan recoveries would continue to drive profitability and support RoA trajectory of ~1% as the overall bad loan pool is still quite large at ~Rs140,000 crore.



**Results (Standalone)** Rs cr **Particulars** Q2FY25 Q2FY24 Y-o-Y (%) Q1FY25 Q-o-Q (%) Interest Income 29,875 26,355 28,556 13% 5% Interest Expenses 19,358 16,432 18,080 18% 7% **Net Interest Income** 10,517 9,923 10,476 6% 0% NIM (%) 2.9 3.1 3.1 Core fee Income 1,581 1,375 2,077 15% -24% Other Income 2,991 1,653 1,533 81% 95% **Net Operating Revenue 7**% 15,089 12,951 14,086 17% 37% **Employee Expenses** 5,750 4,200 4,551 26% Other Opex 2,485 2,535 2,954 -2% -16% 10% **Total Opex** 8,235 6,735 7,505 22% **54.6**% **Cost to Income Ratio (%)** 52.0% 53.3% **Pre Provision Profits** 10% 4% 6,853 6,216 6,581 Provisions & Contingencies - Total 288 1,312 -92% -78% 3,444 **Profit Before Tax** 6,565 2,772 5,269 **137**% 25% 2,262 2,017 123% 12% 1,016 Effective Tax Rate (%) 34.5 36.7 38.3 **Reported Profits** 4,303 1,756 3,252 145% 32% Basic EPS 3.9 1.6 3.0 145% 32% Diluted EPS 3.9 1.6 3.0 RoA (%) 1.0 0.5 0.8 Advances 10,19,595 8,89,920 9,83,998 15% 4% 14,58,342 13,09,910 14,08,247 11% 4% Deposits Gross NPA 47,582 65,563 51,263 -27% -7% Gross NPA Ratio (%) 4.5 7.0 5.0 PCR - (%) 90.2 80.0 88.4 Net NPA 4,674 13,114 5,930 -64% -21% Net NPAs Ratio (%) 0.5 1.5 0.6

Source: Company; Sharekhan Research



#### **Outlook and Valuation**

# ■ Sector Outlook – Deposit mobilisation continues to remain in focus; banks with a superior liability franchise placed better:

System credit growth is slowing and has declined to ~11.5% y-o-y from 16.4% in FY2024 as per the latest fortnight data, mainly driven by slower deposit growth and a high credit-deposit ratio. Deposit growth at 11.8% has started to outpace loan growth marginally. However, deposit growth continues to remain range bound at 11-13% and is mainly led by time deposits rather than CASA. Margins are expected to be under pressure due to elevated cost of term deposits, while a reversal in the rate cycle should further lead to yield pressure. Overall, the asset-quality outlook is stable to positive for the sector, except for the unsecured retail loans and MFI segment. We believe banks with a robust capital base, strong asset quality, and healthy retail deposit franchises are well-placed to capture growth opportunities.

#### ■ Company Outlook – Strong bad loan recoveries continue to boost return ratios

Overall asset quality trends are improving and this is the seventh consecutive quarter. Bad loan recoveries are expected to stay strong. Credit cost is expected to be 25-30 bps of average advances in FY2025E, which should help to sustain RoA at  $\sim$ 1%.

#### ■ Valuation – Maintain Buy on PNB with a revised PT of Rs. 125

Sustained improvement in asset quality is encouraging and outlook remains strong led by strong recoveries from bad loan pools. The net NPL ratio is below the large PSU banks. The bank is reasonably confident that bad loan recoveries would continue to drive profitability and support RoA trajectory of ~1% as the overall bad loan pool is still quite large at ~Rs. 140,000 crore. Also the bank has been guiding that quality of loans sanctioned in post-COVID times is far superior with very low delinquency. Business momentum is expected to remain healthy. At CMP, the stock trades at 0.9x/ 0.8x its FY2025E/FY2026E BV. We maintain Buy on PNB with a revised PT of Rs. 125 given risk reward is favourable given the recent underperformance and also it can now create buffers for the additional ECL provisioning requirement if any within the guided credit cost range and still report RoA at ~1%.

#### Peer valuation

Particulars CMP (Rs		MCAP	MCAP P/E (x)		P/B (x)		RoE (%)		RoA (%)	
Particulars	/ Share) (Rs Cr)		FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Punjab National Bank	101	1,15,975	7.2	6.4	0.9	0.8	13.6	13.0	1.0	1.0
Bank of India	105	47,598	5.5	5.0	0.7	0.6	11.8	11.7	0.9	0.9

Source: Company, Sharekhan estimates



#### **About company**

PNB is a government-owned bank with a network of over 10,159 domestic branches, more than 12,040 ATMs, and 33,010 business correspondents. Around 63% of its branches are in rural and semi-urban areas. PNB's global deposit stood at Rs. 1,458,342 crore and global advances stood at Rs. 10,61,904 crore as of Sep 2024. Capital adequacy ratio (CAR) stands at 16.36%.

#### **Investment theme**

Sustained improvement in asset-quality trend led by lower slippages and strong recoveries is likely to augur well for the earnings trajectory, driven by lower credit cost.

#### **Key Risks**

Economic slowdown, lower recoveries than anticipated, higher slippages, lower margins.

#### **Additional Data**

#### Key management personnel

, , ,	
Arun Kumar Goel	Managing Director and CEO
Kalyan Kumar	Executive Director
Binod Kumar	Executive Director
M. Paramasivam	Executive Director
Bibhu Prasad	Executive Director

Source: Company Website

#### Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Republic of India	70.08
2	Life Insurance Corp of India	7.91
3	Citigroup Global Markets Mauritius	1.15
4	SBI Funds Management Ltd	0.87
5	Vanguard Group Inc/The	0.78
6	Blackrock Inc	0.78
7	Nippon Life India Asset Management	0.43
8	8 Kotak Mahindra Asset Management Co	
9	9 ICICI Prudential Asset Management 0.27	
10	UTI Asset Management Co Ltd	0.26

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

# **Understanding the Sharekhan 3R Matrix**

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
<b>Right Quality</b>	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/ weak realisation environment resulting in margin pressure and detoriating balance sheet
<b>Right Valuation</b>	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative Source: Sharekhan Research	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research



#### **DISCLAIMER**

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/ material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. CIN: - U99999MH1995PLC087498.

Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Correspondence/Administrative Office Address - Gigaplex IT Park, Unit No 1001, 10th Floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai – 400708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD) / MCX - Commodity: INZ000171337; BSE - 748, NSE - 10733, MCX - 56125, DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669 (date of initial registration: 03/07/2004, and valid till 02/07/2026); IRDAI Registered Corporate Agent (Composite) License No. CA0950, valid till June 13, 2027.

Compliance Officer: Ms. Binkle R. Oza; Tel: 022-62263303; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022- 41523200/022-69920600.